<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581384</url>
  </required_header>
  <id_info>
    <org_study_id>15-278</org_study_id>
    <nct_id>NCT02581384</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors</brief_title>
  <official_title>Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is studying stereotactic body radiotherapy (SBRT) as a possible treatment
      for lung relapse of Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, non-rhabdomyosarcoma soft
      tissue sarcoma, Wilms tumor or other primary renal tumor (including clear cell and rhabdoid).
      SBRT is a form of targeted radiotherapy that can treat very small tumors using a few large
      doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a Pilot Study, also known as a Phase I-II study, which means it is the
      first time investigators are examining this study intervention for patients with lung
      recurrence of Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, nonrhabdomyosarcoma soft tissue
      sarcoma, Wilms tumor or other primary renal tumor (including clear cell and rhabdoid). This
      study tests the most appropriate dose, safety and efficacy of SBRT for the treatment of lung
      recurrence of these cancers in children. Standard radiotherapy is typically used to treat
      Ewing sarcoma and is used to treat lung recurrence. SBRT is being used to treat adults with
      small inoperable lung cancers; in such cases, SBRT has been shown to be effective and
      well-tolerated. SBRT is also used to treat bone metastases in adults and children.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>6 Months</time_frame>
    <description>The Phase I portion will evaluate the toxicity profile of each dose level and determine whether a given dose level could move forward to the Phase II portion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response</measure>
    <time_frame>6 weeks</time_frame>
    <description>Response after 6 weeks will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response</measure>
    <time_frame>2 years</time_frame>
    <description>The Kaplan and Meier method will be used to measure relapse time elsewhere in the lung. All patients who takes part in the treatment will be monitored for toxicity, and the percent of patients with various toxicities will be calculated for each dose level.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Ewing Sarcoma</condition>
  <condition>Rhabdomyosarcoma</condition>
  <condition>Wilms Tumor</condition>
  <condition>Osteosarcoma</condition>
  <condition>Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Nos</condition>
  <condition>Renal Tumor</condition>
  <condition>Rhabdoid Tumor</condition>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <condition>Sarcoma</condition>
  <condition>Sarcoma, Ewing</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Stereotactic Body Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic Body Radiotherapy (SBRT)
Different dose levels will be used in the two cohorts.
Ewing sarcoma, rhabdomyosarcoma, and others with non-renal tumor patients begin at a pre-determined dose per protocol.
Wilms tumors or other primary renal tumors renal tumor patients begin at pre-determined dose per protocol.
The two cohorts will be enrolling patients independently and simultaneously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy (SBRT)</intervention_name>
    <arm_group_label>Stereotactic Body Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, non-rhabdomyosarcoma soft
             tissue sarcoma, Wilms tumor or other primary renal tumor (including clear cell and
             rhabdoid)

          -  Age ≤ 21 years;

          -  Must be capable of treatment without general anesthesia

          -  Lesion size 8 mm - 3 cm

          -  Subjects who have lesions within 2 cm of central structures, will be eligible on a
             case by-case basis

          -  Pulmonary metastases found at relapse (does not have to be first relapse); no more
             than 3 lesions per hemi-thorax will be treated but other lesions in the lung may be
             present

          -  Greater than 5 weeks from doxorubicin at the time of consent, with radiation to be
             initiated no less than 6 weeks from doxorubicin

          -  Informed consent/assent

          -  Life expectancy &gt;3 months

          -  Pulmonary Function FEV1 ≥ 50% of predicted;

          -  Concurrent immunotherapy is allowed

        Exclusion Criteria:

          -  Prior whole-lung or hemi-thorax irradiation of greater than 12 Gy received less than 6
             months prior to consent (focal radiotherapy to the thorax is not an exclusion)

          -  Lesion larger than 3 cm in diameter

          -  Patients for whom surgery would be deemed appropriate rather than radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Marcus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen J Marcus, MD</last_name>
    <phone>617-732-8783</phone>
    <email>karen_marcus@dfci.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cierra W Zaslowe-Dude, BA</last_name>
    <phone>6175828987</phone>
    <email>czaslowe-dude@bwh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Marcus, MD</last_name>
      <phone>617-355-8399</phone>
    </contact>
    <investigator>
      <last_name>Karen J Marcus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine Janeway, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Mullen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Marcus, MD</last_name>
      <phone>617-355-8399</phone>
    </contact>
    <investigator>
      <last_name>Karen Marcus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen J Marcus, MD</last_name>
      <phone>617-355-8399</phone>
    </contact>
    <investigator>
      <last_name>Karen J Marcus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine Janeway, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Mullen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2015</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Karen J Marcus, MD</investigator_full_name>
    <investigator_title>Karen J Marcus, M.D.</investigator_title>
  </responsible_party>
  <keyword>Ewing Sarcoma</keyword>
  <keyword>Rhabdomyosarcoma</keyword>
  <keyword>Wilms Tumor</keyword>
  <keyword>Rhabdomyosarcoma of Mediastinum</keyword>
  <keyword>Ewing's Sarcoma Metastatic</keyword>
  <keyword>Ewing Family of Tumors</keyword>
  <keyword>Ewing's Tumor Metastatic</keyword>
  <keyword>Osteosarcoma, Metastatic</keyword>
  <keyword>Osteosarcoma in Children</keyword>
  <keyword>Rhabdoid Tumor</keyword>
  <keyword>Lung Metastasis</keyword>
  <keyword>Radiation for Children</keyword>
  <keyword>SBRT for children</keyword>
  <keyword>Stereotactic Body Radiotherapy</keyword>
  <keyword>Pulmonary Metastasis</keyword>
  <keyword>Lung Metastasis in Children</keyword>
  <keyword>Pulmonary Metastasis in Children</keyword>
  <keyword>Comfort Care</keyword>
  <keyword>Palliative Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Wilms Tumor</mesh_term>
    <mesh_term>Rhabdoid Tumor</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

